Repare Therapeutics Administers First Camonsertib Dose in NSCLC TRESR Trial Expansion

Repare Therapeutics Inc. (Nasdaq: RPTX), a precision oncology firm in the clinical-stage, has announced that the first patient has been treated in their camonsertib monotherapy expansion for non-small cell lung cancer (NSCLC) within the TRESR clinical trial. This marks a significant milestone for the Company, which has recently regained global rights to camonsertib.

Maria Koehler, MD, PhD, the Executive Vice President and Chief Medical Officer of Repare, shared her excitement about this rapid progress. She emphasized that camonsertib has shown potential in extending progression-free survival in patients with ATM-mutated NSCLC. This specific mutation affects a significant number of patients, specifically around 5,000 in the United States, UK, and top four EU markets. Camonsertib could address this unmet need where the current standard treatments offer only about four months of progression-free survival with low response rates.

The TRESR clinical trial, also known as Treatment Enabled by SNIPRx, is a multicenter, open-label trial in its Phase 1/2 stage, designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of camonsertib, either alone or in combination with other treatments. The NSCLC expansion aims to enroll up to 20 patients who have ATR-inhibitor sensitizing mutations in their NSCLC. The primary goal is to evaluate camonsertib's efficacy at the recommended Phase 2 dosage. Given the limited treatment options for recurrent NSCLC, camonsertib offers a promising oral therapy with a well-established safety profile. Repare expects to have potential data readout from this expansion by 2025.

Repare Therapeutics leverages a unique synthetic lethality approach to discover and develop new cancer therapies. Their proprietary SNIPRx® platform, enabled by CRISPR technology, allows them to systematically target cancer therapies that exploit genomic instability, including those involved in DNA damage repair. The Company's product pipeline includes several promising candidates: lunresertib, a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib, a leading ATR inhibitor also in Phase 1/2 development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, which is a preclinical Polθ ATPase inhibitor program; and other undisclosed preclinical programs.

With a clear focus on precision oncology, Repare Therapeutics aims to develop targeted therapies that can offer substantial benefits to patients with specific genetic profiles, particularly those with few existing treatment options. Their efforts, driven by a robust pipeline and innovative approaches, hold promise for transforming cancer treatment paradigms and improving patient outcomes.

Repare's SNIPRx® is a registered trademark, underscoring the company's commitment to cutting-edge technological advancements in oncology. The clinical advancements and ongoing trials underscore Repare’s commitment to addressing critical gaps in cancer treatment, particularly for those with specific genetic vulnerabilities. The company’s proactive approach and rapid trial expansions highlight its dedication to bringing new, effective cancer treatments to market to meet pressing medical needs.